C5 and Bone marrow hypocellularity: Crovalimab's sustained C5 inhibition (t1/2=53.1 days [12] vs. eculizumab's 187.7 hours [13]) might lead to platelet recovery and suggest the beneficial role of crovalimab in treating bone marrow failure-associated PNH.